TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma

Camille Guillerey, Heidi Harjunpää, Nadège Carrié, Sahar Kassem, Tricia Teo, Kim Miles, Sophie Krumeich, Marianne Weulersse, Marine Cuisinier, Kimberley Stannard, Yuan Yu, Simone A. Minnie, Geoffrey R. Hill, William C. Dougall, Hervé Avet-Loiseau, Michele W.L. Teng, Kyohei Nakamura, Ludovic Martinet, Mark J. Smyth

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD81 T cells. TIGIT1 CD81 T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk∗MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD81 T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.

Original languageEnglish
Pages (from-to)1689-1694
Number of pages6
JournalBlood
Volume132
Issue number16
DOIs
Publication statusPublished - 18 Oct 2018

Fingerprint

T-cells
Multiple Myeloma
Immunoglobulins
Immunity
T-Lymphocytes
Immunoglobulin Domains
Programmed Cell Death 1 Receptor
Therapeutics
Tumor Burden
Tumors
Monoclonal Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., ... Smyth, M. J. (2018). TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma. Blood, 132(16), 1689-1694. https://doi.org/10.1182/blood-2018-01-825265

TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma. / Guillerey, Camille; Harjunpää, Heidi; Carrié, Nadège; Kassem, Sahar; Teo, Tricia; Miles, Kim; Krumeich, Sophie; Weulersse, Marianne; Cuisinier, Marine; Stannard, Kimberley; Yu, Yuan; Minnie, Simone A.; Hill, Geoffrey R.; Dougall, William C.; Avet-Loiseau, Hervé; Teng, Michele W.L.; Nakamura, Kyohei; Martinet, Ludovic; Smyth, Mark J.

In: Blood, Vol. 132, No. 16, 18.10.2018, p. 1689-1694.

Research output: Contribution to journalArticle

Guillerey, C, Harjunpää, H, Carrié, N, Kassem, S, Teo, T, Miles, K, Krumeich, S, Weulersse, M, Cuisinier, M, Stannard, K, Yu, Y, Minnie, SA, Hill, GR, Dougall, WC, Avet-Loiseau, H, Teng, MWL, Nakamura, K, Martinet, L & Smyth, MJ 2018, 'TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma', Blood, vol. 132, no. 16, pp. 1689-1694. https://doi.org/10.1182/blood-2018-01-825265
Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K et al. TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma. Blood. 2018 Oct 18;132(16):1689-1694. https://doi.org/10.1182/blood-2018-01-825265
Guillerey, Camille ; Harjunpää, Heidi ; Carrié, Nadège ; Kassem, Sahar ; Teo, Tricia ; Miles, Kim ; Krumeich, Sophie ; Weulersse, Marianne ; Cuisinier, Marine ; Stannard, Kimberley ; Yu, Yuan ; Minnie, Simone A. ; Hill, Geoffrey R. ; Dougall, William C. ; Avet-Loiseau, Hervé ; Teng, Michele W.L. ; Nakamura, Kyohei ; Martinet, Ludovic ; Smyth, Mark J. / TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma. In: Blood. 2018 ; Vol. 132, No. 16. pp. 1689-1694.
@article{6c7e18df7a6f403a96cccda1e7be8434,
title = "TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma",
abstract = "Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD81 T cells. TIGIT1 CD81 T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk∗MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD81 T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.",
author = "Camille Guillerey and Heidi Harjunp{\"a}{\"a} and Nad{\`e}ge Carri{\'e} and Sahar Kassem and Tricia Teo and Kim Miles and Sophie Krumeich and Marianne Weulersse and Marine Cuisinier and Kimberley Stannard and Yuan Yu and Minnie, {Simone A.} and Hill, {Geoffrey R.} and Dougall, {William C.} and Herv{\'e} Avet-Loiseau and Teng, {Michele W.L.} and Kyohei Nakamura and Ludovic Martinet and Smyth, {Mark J.}",
year = "2018",
month = "10",
day = "18",
doi = "10.1182/blood-2018-01-825265",
language = "English",
volume = "132",
pages = "1689--1694",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - TIGIT immune checkpoint blockade restores CD81 T-cell immunity against multiple myeloma

AU - Guillerey, Camille

AU - Harjunpää, Heidi

AU - Carrié, Nadège

AU - Kassem, Sahar

AU - Teo, Tricia

AU - Miles, Kim

AU - Krumeich, Sophie

AU - Weulersse, Marianne

AU - Cuisinier, Marine

AU - Stannard, Kimberley

AU - Yu, Yuan

AU - Minnie, Simone A.

AU - Hill, Geoffrey R.

AU - Dougall, William C.

AU - Avet-Loiseau, Hervé

AU - Teng, Michele W.L.

AU - Nakamura, Kyohei

AU - Martinet, Ludovic

AU - Smyth, Mark J.

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD81 T cells. TIGIT1 CD81 T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk∗MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD81 T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.

AB - Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD81 T cells. TIGIT1 CD81 T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk∗MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD81 T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.

UR - http://www.scopus.com/inward/record.url?scp=85054876519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054876519&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-01-825265

DO - 10.1182/blood-2018-01-825265

M3 - Article

VL - 132

SP - 1689

EP - 1694

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -